WO2024254507A3 - Traitement de lymphomes b avec des cellules nk et un anticorps ciblant cd20 - Google Patents

Traitement de lymphomes b avec des cellules nk et un anticorps ciblant cd20 Download PDF

Info

Publication number
WO2024254507A3
WO2024254507A3 PCT/US2024/033083 US2024033083W WO2024254507A3 WO 2024254507 A3 WO2024254507 A3 WO 2024254507A3 US 2024033083 W US2024033083 W US 2024033083W WO 2024254507 A3 WO2024254507 A3 WO 2024254507A3
Authority
WO
WIPO (PCT)
Prior art keywords
cells
treatment
cell lymphomas
targeted antibody
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2024/033083
Other languages
English (en)
Other versions
WO2024254507A2 (fr
Inventor
Fred ASLAN
Thorsten Graef
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Artiva Biotherapeutics Inc
Original Assignee
Artiva Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Artiva Biotherapeutics Inc filed Critical Artiva Biotherapeutics Inc
Publication of WO2024254507A2 publication Critical patent/WO2024254507A2/fr
Publication of WO2024254507A3 publication Critical patent/WO2024254507A3/fr
Anticipated expiration legal-status Critical
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne, entre autres, des méthodes de traitement de lymphomes B avec des cellules NK et un anticorps ciblant CD20.
PCT/US2024/033083 2023-06-09 2024-06-07 Traitement de lymphomes b avec des cellules nk et un anticorps ciblant cd20 Pending WO2024254507A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363507393P 2023-06-09 2023-06-09
US63/507,393 2023-06-09

Publications (2)

Publication Number Publication Date
WO2024254507A2 WO2024254507A2 (fr) 2024-12-12
WO2024254507A3 true WO2024254507A3 (fr) 2025-01-30

Family

ID=93796421

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/033083 Pending WO2024254507A2 (fr) 2023-06-09 2024-06-07 Traitement de lymphomes b avec des cellules nk et un anticorps ciblant cd20

Country Status (1)

Country Link
WO (1) WO2024254507A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110121505B (zh) 2016-12-28 2023-08-01 株式会社绿十字细胞治疗 嵌合抗原受体和表达其的自然杀伤细胞
US11649294B2 (en) 2017-11-14 2023-05-16 GC Cell Corporation Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022133057A1 (fr) * 2020-12-17 2022-06-23 Artiva Biotherapeutics, Inc. Traitement du cancer par des cellules nk et un anticorps ciblant cd20
WO2022216811A2 (fr) * 2021-04-08 2022-10-13 Artiva Biotherapeutics, Inc. Récepteur d'antigène chimère comprenant un anticorps anti-cd19 ou un fragment de liaison à l'antigène de celui-ci et cellules tueuses naturelles le comprenant

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022133057A1 (fr) * 2020-12-17 2022-06-23 Artiva Biotherapeutics, Inc. Traitement du cancer par des cellules nk et un anticorps ciblant cd20
WO2022216811A2 (fr) * 2021-04-08 2022-10-13 Artiva Biotherapeutics, Inc. Récepteur d'antigène chimère comprenant un anticorps anti-cd19 ou un fragment de liaison à l'antigène de celui-ci et cellules tueuses naturelles le comprenant

Also Published As

Publication number Publication date
WO2024254507A2 (fr) 2024-12-12

Similar Documents

Publication Publication Date Title
WO2024254507A3 (fr) Traitement de lymphomes b avec des cellules nk et un anticorps ciblant cd20
EP4549582A3 (fr) Procédés d'analyse spatiale à l'aide d'une déplétion d'arn ciblée
EP4265568A3 (fr) Procédé de préparation d'un batterie secondaire
WO2022272292A3 (fr) Cellules ingéniérisées pour une thérapie
WO2021257989A3 (fr) Méthodes et compositions pour moduler des cellules et des membranes cellulaires
EP4319772A4 (fr) Traitement du cancer avec des cellules nk et un anticorps ciblant l'egfr
EP4319769A4 (fr) Traitement du cancer par des cellules nk et un anticorps ciblant le cd20
WO2023122755A3 (fr) Cuve à circulation et procédés
MX2023014073A (es) Receptores de linfocitos t que se dirigen a mutaciones de ras y usos de los mismos.
WO2022150610A3 (fr) Récepteurs de lymphocytes t spécifiques à sars-cov-2, matériels correspondants et méthodes d'utilisation
EP4383362A4 (fr) Matériau de cathode, batterie utilisant ledit matériau de cathode, et procédé de charge de batterie
EP4310956A4 (fr) Composition de matériau carboné, procédé de production d'une composition de matériau carboné, électrode négative et batterie secondaire
MX2022004443A (es) Metodos para usar inmunoconjugados anti-cd79b para tratar linfoma difuso de linfocitos b grandes.
MX2025005088A (es) Métodos para tratar cánceres
WO2021146620A3 (fr) Récepteurs antigéniques chimériques pour éliminer un amyloïde
CR20230490A (es) Anticuerpo biespecífico anti–cldn4/anti–cd137
WO2023086906A3 (fr) Anticorps sirp gamma et leurs utilisations
MX2020003395A (es) Composiciones y metodos para tratar linfoma difuso de celulas b grandes.
WO2023081455A3 (fr) Cellules immunitaires exprimant le transporteur de glucose 5 (glut5) et compositions et procédés les comprenant
WO2021203061A8 (fr) Thérapie immunomodulatrice de cellules souches pour une infection par covid-19
EP4148831A4 (fr) Précurseur de matériau actif d'électrode positive pour batterie secondaire au lithium, procédé de production de précurseur de matériau actif d'électrode positive pour batterie secondaire au lithium et procédé de production de matériau actif d'électrode positive pour batterie secondaire au lithium
EP4207370A4 (fr) Matériau actif d'électrode positive pour accumulateur à électrolyte non aqueux et accumulateur à électrolyte non aqueux
MX2021005847A (es) Gen suicida.
WO2022212525A9 (fr) Thérapie de cellules car t et ifn gamma
WO2022226346A3 (fr) Systèmes de production stables pour la production de vecteurs lentiviraux

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24820165

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE